EMA Withdrawn: Qtrilmet (metformin hydrochloride;saxagliptin;dapagliflozin) — AstraZeneca AB

View source ↗

Summary

EMA has withdrawn Qtrilmet (metformin hydrochloride; saxagliptin; dapagliflozin) for Type 2 diabetes from AstraZeneca AB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Qtrilmet
• metformin hydrochloride; saxagliptin; dapagliflozin

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 14/08/2020